Skip to main content
Top
Published in: Diabetology International 4/2016

01-12-2016 | Original Article

Serum uric acid levels are associated with a high risk of rapid chronic kidney disease progression among patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 12)]

Authors: Hirohito Kuwata, Shintaro Okamura, Yasuaki Hayashino, Hitoshi Ishii, Satoru Tsujii

Published in: Diabetology International | Issue 4/2016

Login to get access

Abstract

Background

We assessed the prospective association between baseline serum uric acid (SUA) concentrations and consequent risk of chronic kidney disease (CKD) progression in type 2 diabetes patients.

Methods

Longitudinal data from a Japanese diabetes registry including 3454 type 2 diabetes patients were obtained. To assess the independent correlations between SUA and rapid CKD progression [i.e., 30 % reduction in estimated glomerular filtration rate (eGFR) over 2 years], participants were divided into five groups based on SUA levels: <5.0, ≥5.0–6.0, ≥6.0–7.0, ≥7.0–8.0, and ≥8.0 mg/dl. Cox proportional hazards model adjusted for potential confounders was used for analysis.

Results

After 2 years, rapid CKD progression was recognized in 169 patients (4.89 %) who showed longer duration of type 2 diabetes (15.5 vs. 13.5 years, p = 0.005); higher systolic blood pressure (142.0 vs. 138.3 mmHg, p = 0.016), SUA (6.15 vs. 5.32 mg/dl, p < 0.001), and urinary albumin–creatinine ratio (1127.4 vs. 184.7 mg/gCr, p < 0.001); and lower diastolic blood pressure (69.7 vs. 72.8 mmHg, p = 0.003). Multivariate ratios for rapid CKD progression were 1.19 (p = 0.371), 1.02 (p = 0.937), 1.18 (p = 0.625), and 3.04 (p = 0.004), respectively, for the first, third, fourth, and fifth serum UA range groups; a second group was used as a reference.

Conclusions

Higher SUA levels, independent of possible confounders, were associated with rapid eGFR decline and CKD progression in type 2 diabetes patients. SUA may be a useful biomarker for predicting future risk of rapid diabetic CKD progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fenwick E, Rees G, Pesudovs K, et al. Social and emotional impact of diabetic retinopathy: a review. Clin Experiment Ophthalmol. 2012;40:27–38.CrossRefPubMed Fenwick E, Rees G, Pesudovs K, et al. Social and emotional impact of diabetic retinopathy: a review. Clin Experiment Ophthalmol. 2012;40:27–38.CrossRefPubMed
2.
go back to reference Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127–33.CrossRefPubMed Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127–33.CrossRefPubMed
3.
go back to reference Eckardt K-U, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158–69.CrossRefPubMed Eckardt K-U, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158–69.CrossRefPubMed
5.
go back to reference Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001;59:702–9.CrossRefPubMed Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001;59:702–9.CrossRefPubMed
6.
go back to reference Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–507.CrossRefPubMed Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–507.CrossRefPubMed
7.
go back to reference Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes. 1994;43:1046–51.CrossRefPubMed Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes. 1994;43:1046–51.CrossRefPubMed
8.
go back to reference Ueda H, Ishimura E, Shoji T, et al. Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care. 2003;26:1530–4.CrossRefPubMed Ueda H, Ishimura E, Shoji T, et al. Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care. 2003;26:1530–4.CrossRefPubMed
9.
go back to reference Cirillo P, Sato W, Reungjui S, et al. Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol. 2006;17:S165–16810.CrossRefPubMed Cirillo P, Sato W, Reungjui S, et al. Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol. 2006;17:S165–16810.CrossRefPubMed
11.
go back to reference Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407–13.CrossRefPubMedPubMedCentral Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407–13.CrossRefPubMedPubMedCentral
12.
go back to reference Nakagawa T, Kang D-H, Feig D, et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int. 2006;69:1722–5.CrossRefPubMed Nakagawa T, Kang D-H, Feig D, et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int. 2006;69:1722–5.CrossRefPubMed
13.
go back to reference Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010;33:1337–43.CrossRefPubMedPubMedCentral Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010;33:1337–43.CrossRefPubMedPubMedCentral
14.
go back to reference Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35:99–104.CrossRefPubMed Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35:99–104.CrossRefPubMed
15.
go back to reference Tanaka K, Hara S, Hattori M, et al. Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes. J Diabetes Investig. 2015;6:98–10416.CrossRefPubMed Tanaka K, Hara S, Hattori M, et al. Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes. J Diabetes Investig. 2015;6:98–10416.CrossRefPubMed
16.
go back to reference De Cosmo S, Viazzi F, Pacilli A, et al. AMD-Annals Study Group. Serum uric acid and risk of ckd in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10:1921–9.CrossRefPubMedPubMedCentral De Cosmo S, Viazzi F, Pacilli A, et al. AMD-Annals Study Group. Serum uric acid and risk of ckd in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10:1921–9.CrossRefPubMedPubMedCentral
17.
go back to reference Hayashino Y, Tsujii S, Ishii H. High frequency of non-nocturnal hypoglycemia was associated with poor sleep quality measure by Pittsburg Sleep Quality Index in patients with diabetes receiving insulin therapy: Diabetes Distress and Care Registry at Tenri (DDCRT 4). Exp Clin Endocrinol Diabetes. 2013;121:628–34.CrossRefPubMed Hayashino Y, Tsujii S, Ishii H. High frequency of non-nocturnal hypoglycemia was associated with poor sleep quality measure by Pittsburg Sleep Quality Index in patients with diabetes receiving insulin therapy: Diabetes Distress and Care Registry at Tenri (DDCRT 4). Exp Clin Endocrinol Diabetes. 2013;121:628–34.CrossRefPubMed
18.
go back to reference Hayashino Y, Mashitani T, Tsujii S, Ishii H. Elevated levels of hs-CRP are associated with high prevalence of depression in japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6). Diabetes Care. 2014;37:2459–65.CrossRefPubMed Hayashino Y, Mashitani T, Tsujii S, Ishii H. Elevated levels of hs-CRP are associated with high prevalence of depression in japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6). Diabetes Care. 2014;37:2459–65.CrossRefPubMed
19.
go back to reference Hayashino Y, Okamura S, Matsunaga S, Tsujii S, Ishii H. The association between problem areas in diabetes scale scores and glycemic control is modified by types of diabetes therapy: diabetes distress and care registry in Tenri (DDCRT 2). Diabetes Res Clin Pract. 2012;97:405–10.CrossRefPubMed Hayashino Y, Okamura S, Matsunaga S, Tsujii S, Ishii H. The association between problem areas in diabetes scale scores and glycemic control is modified by types of diabetes therapy: diabetes distress and care registry in Tenri (DDCRT 2). Diabetes Res Clin Pract. 2012;97:405–10.CrossRefPubMed
20.
go back to reference Mashitani T, Hayashino Y, Okamura S, et al. Diabetes treatment-related quality of life is associated with levels of self-care activities in insulin injection among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 8). Acta Diabetol 2015. 2015. Mashitani T, Hayashino Y, Okamura S, et al. Diabetes treatment-related quality of life is associated with levels of self-care activities in insulin injection among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 8). Acta Diabetol 2015. 2015.
21.
go back to reference Mashitani T, Hayashino Y, Okamura S, et al. Patient-reported adherence to insulin regimen is associated with glycemic control among Japanese patients with type 2 diabetes: diabetes Distress and Care Registry at Tenri (DDCRT 3). Diabetes Res Clin Pract. 2013;100:189–94.CrossRefPubMed Mashitani T, Hayashino Y, Okamura S, et al. Patient-reported adherence to insulin regimen is associated with glycemic control among Japanese patients with type 2 diabetes: diabetes Distress and Care Registry at Tenri (DDCRT 3). Diabetes Res Clin Pract. 2013;100:189–94.CrossRefPubMed
22.
go back to reference Mashitani T, Hayashino Y, Okamura S, Tsujii S, Ishii H. Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetic patients: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 5)]. Diabetes Care. 2014;37:252–8.CrossRefPubMed Mashitani T, Hayashino Y, Okamura S, Tsujii S, Ishii H. Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetic patients: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 5)]. Diabetes Care. 2014;37:252–8.CrossRefPubMed
23.
go back to reference Tsujii S, Hayashino Y, Ishii H. Diabetes distress, but not depressive symptoms, is associated with glycaemic control among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 1). Diabet Med. 2012;29:1451–5.CrossRefPubMed Tsujii S, Hayashino Y, Ishii H. Diabetes distress, but not depressive symptoms, is associated with glycaemic control among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 1). Diabet Med. 2012;29:1451–5.CrossRefPubMed
24.
go back to reference Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28.CrossRefPubMedPubMedCentral Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28.CrossRefPubMedPubMedCentral
25.
go back to reference Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
26.
go back to reference Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–31.CrossRefPubMedPubMedCentral Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–31.CrossRefPubMedPubMedCentral
27.
go back to reference Fu C-C, Wu D-A, Wang J-H, Yang W-C, Tseng C-H. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients. Acta Diabetol. 2009;46:127–34.CrossRefPubMed Fu C-C, Wu D-A, Wang J-H, Yang W-C, Tseng C-H. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients. Acta Diabetol. 2009;46:127–34.CrossRefPubMed
28.
go back to reference Fukui M, Tanaka M, Shiraishi E, et al. Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism. 2008;57:625–9.CrossRefPubMed Fukui M, Tanaka M, Shiraishi E, et al. Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism. 2008;57:625–9.CrossRefPubMed
29.
go back to reference Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.CrossRefPubMed Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.CrossRefPubMed
30.
go back to reference Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269–75.CrossRefPubMed Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269–75.CrossRefPubMed
31.
go back to reference Menè P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens. 2008;26:2085–92.CrossRefPubMed Menè P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens. 2008;26:2085–92.CrossRefPubMed
32.
go back to reference Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl JMed. 2008;359:1811–21.CrossRef Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl JMed. 2008;359:1811–21.CrossRef
33.
go back to reference Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932–5.CrossRefPubMed Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932–5.CrossRefPubMed
34.
go back to reference Hovind P, Rossing P, Tarnow L. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes. 2009;58:2–5.CrossRef Hovind P, Rossing P, Tarnow L. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes. 2009;58:2–5.CrossRef
35.
go back to reference Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am. 1990;16:539–50.PubMed Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am. 1990;16:539–50.PubMed
36.
go back to reference Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765–70.CrossRefPubMed Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765–70.CrossRefPubMed
37.
go back to reference Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349–55.CrossRefPubMed Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349–55.CrossRefPubMed
38.
go back to reference Japanese Society of Gout and Nucleic Acid Metabolissm. Japanese guideline for the management of hyperuricemia and gout: second edition. Gout Nucleic acid Res. 2010;34:109–44. Japanese Society of Gout and Nucleic Acid Metabolissm. Japanese guideline for the management of hyperuricemia and gout: second edition. Gout Nucleic acid Res. 2010;34:109–44.
39.
go back to reference Goicoechea M, De Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.CrossRefPubMedPubMedCentral Goicoechea M, De Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.CrossRefPubMedPubMedCentral
40.
go back to reference Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin ii antagonist losartan trial. Hypertension. 2011;58:2–7.CrossRefPubMed Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin ii antagonist losartan trial. Hypertension. 2011;58:2–7.CrossRefPubMed
41.
go back to reference Liu P, Chen Y, Wang B, et al. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol. 2015;83:475–82.CrossRef Liu P, Chen Y, Wang B, et al. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol. 2015;83:475–82.CrossRef
42.
go back to reference Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404.CrossRefPubMedPubMedCentral Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404.CrossRefPubMedPubMedCentral
Metadata
Title
Serum uric acid levels are associated with a high risk of rapid chronic kidney disease progression among patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 12)]
Authors
Hirohito Kuwata
Shintaro Okamura
Yasuaki Hayashino
Hitoshi Ishii
Satoru Tsujii
Publication date
01-12-2016
Publisher
Springer Japan
Published in
Diabetology International / Issue 4/2016
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-016-0254-2

Other articles of this Issue 4/2016

Diabetology International 4/2016 Go to the issue